A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506863-32-00

Acronym

BN44083

Enrollment

Registered

2024-07-11

Start date

2023-07-25

Completion date

Unknown

Last updated

2025-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis (MS)

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Croatia, Czechia

None listed

Source: EU CTIS · Data processed: Feb 4, 2026